trending Market Intelligence /marketintelligence/en/news-insights/trending/umvw752e6pnypzwohhqvra2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Lilly to acquire pain drug program from Hydra Biosciences

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Lilly to acquire pain drug program from Hydra Biosciences

Eli Lilly and Co. will acquire a preclinical pain drug program from Hydra Biosciences Inc.

The Indianapolis-based company will acquire all assets related to Cambridge, Mass.-based Hydra's pre-clinical program related to the transient receptor potential ankyrin 1, or TRPA1, inhibiting drugs.

TRPA1 is a protein whose function includes an electrical signaling, among others, and is responsible for sensations of pain, pressure and warmth, among other things. Hydra's program is aimed at developing drugs that inhibit these proteins and act as a potential treatment of chronic pain syndromes.

Financial terms of the transaction were not disclosed.

Lilly said the transaction will have no change to its non-GAAP per share guidance for 2018.